Results 51 to 60 of about 28,270 (206)

Does the level of myocardial injury differ in primary angioplasty patients loaded first with clopidogrel and the ones with ticagrelor?

Anatolian Journal of Cardiology, 2020
Objective: In daily clinical practice, we encounter ST segment elevation myocardial infarction (STEMI) patients loaded with clopidogrel upon admission to primary angioplasty.
Nil Ozyuncu, Hüseyin Göksülük, Turkan Seda Tan, Kerim Esenboga, Yusuf Atmaca, Çetin Erol   +5 more
doaj   +1 more source

Contemporary NSTEMI management: the role of the hospitalist. [PDF]

, 2019
Non-ST-segment elevation myocardial infarction (NSTEMI) is defined as elevated cardiac biomarkers of necrosis in the absence of persistent ST-segment elevation in the setting of anginal symptoms or other acute event.
Amin, Alpesh, Cohen, Marc, Deitelzweig, Steven, DiLascia, Christopher, Fanikos, John, Kaatz, Scott, Pollack, Charles V, Slattery, David, Tuder, Regan, Wang, Tracy   +9 more
core   +1 more source

Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study [PDF]

, 2016
Microvascular injury is present in a large proportion of patients with ST-elevation myocardial infarction (STEMI) despite successful revascularization. Ticagrelor potentially mitigates this process by exerting additional adenosine-mediated effects.
Diletti, R. (Roberto), Escaned, J. (Javier), Janssens, G.N. (Gladys N.), Leeuwen, M.A.H. (Maarten) van, Nijveldt, R. (Robin), Royen, N. (Niels) van, Valgimigli, M. (Marco), van der Hoeven, N.W. (Nina W.), Von Birgelen, C. (Clemens), Waard, G.A. (Guus) de, Zijlstra, F. (Felix)   +10 more
core   +1 more source

Quantitative prediction of intravenous drug interactions caused by cytochromes P450 inhibitors and inducers

British Journal of Clinical Pharmacology, EarlyView.
Background Aims Pharmacokinetic interaction studies typically focus on oral administration, but intravenous (IV) administration bypasses intestinal degradation and hepatic first‐pass metabolism, leading to distinct drug–drug interaction (DDI) magnitude. This study aimed to develop a predictive model for DDIs involving IV‐administered drugs.
Vianney Tuloup, Michel Tod, Laurent Bourguignon   +2 more
wiley   +1 more source

Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats

Pharmaceutics, 2019
Tadalafil is a cytochrome P450 (CYP) 3A4 substrate. Because there are few data on drug-drug interactions, it is advisable to take sufficient consideration when co-administering tadalafil with CYP3A4 inducers or inhibitors.
Young-Guk Na, Jin-Ju Byeon, Hyun Wook Huh, Min-Ki Kim, Young G. Shin, Hong-Ki Lee, Cheong-Weon Cho   +6 more
doaj   +1 more source

Variability in ACT Response to Standard UFH Bolus During PCI: A Prospective Study on Determinants of Subtherapeutic Anticoagulation

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Unfractionated heparin (UFH) remains the standard anticoagulant during percutaneous coronary intervention (PCI), with guidelines recommending a target activated clotting time (ACT) of ≥250 s. However, despite receiving a standardized bolus dose, many patients fail to achieve this target.
Manh Cuong Vu, Antonin Trimaille, Amandine Granier, Adrien Carmona, Anis Elidrissi, Marion Kibler, Laurence Jesel, Patrick Ohlmann, Laurent Sattler, Olivier Morel   +9 more
wiley   +1 more source

Ticagrelor Loading on ST-Elevation Myocardial Infarction: Interaction With Prodromal Angina on Infarct Size and Clinical Events

Journal of Cardiovascular Pharmacology and Therapeutics, 2023
Introduction: Ticagrelor might reduce infarct size by exerting a more potent antiplatelet effect or by promoting a potential conditioning stimulus in ST-elevation myocardial infarction (STEMI) patients.
João Pedro Faria MD, Pedro Oliveira PhD, André Alexandre MD, David Sá Couto MD, Ricardo Costa MD, Andreia Campinas MD, André Frias MD, Bruno Brochado MD, Raquel Santos MD, João Silveira MD, Severo Torres MD, André Luz MD, PhD, FESC   +11 more
doaj   +1 more source

Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand [PDF]

, 2014
Objectives: To evaluate the long-term cost-effectiveness of ticagrelor and ASA versus generic and branded clopidogrel and ASA in patients with ACS based on a Thai cost database.
Permsuwan, Unchalee, Tinmanee, Sirana, Yamwong, Sukit   +2 more
core   +1 more source

Influence of the Residual Gensini Score on Prognosis of Patients With ST‐Elevation Myocardial Infarction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background The residual Gensini score (rGS) was developed to quantify the severity of coronary atheroma burden after coronary revascularisation. The predictive value of the rGS for clinical outcomes in patients with ST‐segment elevation myocardial infarction (STEMI) remains unexplored.
Batric Popovic, Nassima Djaballah, Mirela Tomic, Renaud Fay, Victorine Fraichot, Florian Eggenspieler, Pierre Adrien Metzdorf, Jeanne Varlot, Edoardo Camenzind   +8 more
wiley   +1 more source

Progress in the clinical effects and adverse reactions of ticagrelor

Thrombosis Journal
Background Ticagrelor is a novel receptor antagonist that selectively binds to the P2Y12 receptor, thereby inhibiting adenosine diphosphate (ADP)-mediated platelet aggregation.
Peng Wei, Xiaoqing Wang, Qiang Fu, Bangming Cao   +3 more
doaj   +1 more source